Patents by Inventor David M LU

David M LU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rationale-based design of a targeted therapy for cancer
    Patent number: 10449202
    Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: October 22, 2019
    Assignee: CELESTRA LIFE SCIENCE LLC
    Inventors: Allen J. Lee, Jason J. Lee, David M. Lu, Ruey-Min Lee
  • RATIONALE-BASED DESIGN OF A TARGETED THERAPY FOR CANCER
    Publication number: 20180117061
    Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
    Type: Application
    Filed: July 18, 2017
    Publication date: May 3, 2018
    Inventors: Allen J. Lee, Jason J. Lee, David M. Lu, Ruey-Min Lee
  • Rationale-based design of a targeted therapy for cancer
    Patent number: 9782418
    Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: October 10, 2017
    Assignee: Celestra Life Science LLC
    Inventors: Allen J. Lee, Jason J. Lee, David M. Lu, Ruey-Min Lee
  • RATIONALE-BASED DESIGN OF A TARGETED THERAPY FOR CANCER
    Publication number: 20160303140
    Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.
    Type: Application
    Filed: December 3, 2014
    Publication date: October 20, 2016
    Inventors: Allen J. LEE, Jason J LEE, David M LU, Ruey-Min LEE